BioCryst Pharmaceuticals | BCRX - Assets


BioCryst Pharmaceuticals reported $465.05M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Chugai Pharma JPY 2.27T 203.49B Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
DBV Technologies USD 233.72M 123.22M Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026